| Ytd | 37.90% | |
| 1y | 37.90% |
| Open | 31.96 | Prev Close | 32.23 | Low | 30.86 | High | 32.31 | Mkt Cap | 1.71B |
| Vol | 534.76K | Avg Vol | 296.72K | EPS | -1.21 | P/E | N/A | Forward P/E | -15.95 |
| Beta | 1.69 | Short Ratio | 14.19 | Inst. Own | 74.20% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-11 | 50-d Avg | 21.44 | 200-d Avg | 20.10 | 1yr Est | 33.88 |
Top Wall Street analysts changed outlook on top names. For all changes, including upgrades/downgrade
Raymond James analyst Christopher Raymond initiates coverage on Aktis Oncology (NASDAQ:AKTS) with
U.S. stocks were mixed, with the Dow Jones gaining 100 points. Rezolve AI (RZLV) jumped 11.9%, and o
HC Wainwright & Co. analyst Robert Burns maintains Aktis Oncology (NASDAQ:AKTS) with a Buy an